(Q40568751)

21 September 2017

title

Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome (English)

1 reference

21 September 2017

0 references

0 references

schizophrenic prodrome

1 reference

11

Thomas H McGlashan

1 reference

21 September 2017

5

Jean Addington

1 reference

21 September 2017

Scott W Woods

1

1 reference

21 September 2017

Alan Breier

2

1 reference

21 September 2017

Robert B Zipursky

3

1 reference

21 September 2017

Diana O Perkins

4

1 reference

21 September 2017

Tandy J Miller

6

1 reference

21 September 2017

Keith A Hawkins

7

1 reference

21 September 2017

Eva Marquez

8

1 reference

21 September 2017

Stacy R Lindborg

9

1 reference

21 September 2017

Mauricio Tohen

10

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

21 September 2017

published in

Biological Psychiatry

1 reference

21 September 2017

volume

54

1 reference

21 September 2017

issue

4

1 reference

21 September 2017

page(s)

453-464

1 reference

A rating scale for drug-induced akathisia

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

West London first-episode study of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Duration of untreated psychosis predicts treatment outcome in an early psychosis program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Deficit states in schizophrenia and their association with the length of illness and gender

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Putatively psychosis-prone subjects 10 years later

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

A randomised controlled trial of prophylactic neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Duration of untreated psychosis and the long-term course of schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Causes and consequences of duration of untreated psychosis in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Early intervention for first episodes of schizophrenia: a preliminary exploration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Features of structural brain abnormality detected in first-episode psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Global assessment of functioning. A modified scale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Factorial structure of the Scale of Prodromal Symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Informed Consent in Early Psychosis Research: National Institute of Mental Health workshop, November 15, 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Lack of association between duration of untreated illness and severity of cognitive and structural brain deficits at the first episode of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The positive and negative syndrome scale (PANSS) for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Diagnosing schizophrenia in the initial prodromal phase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Olanzapine-associated diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

A ten-year follow-up study of Chinese schizophrenics in Hong Kong

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Duration of psychosis and outcome in first-episode schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Progressive atrophy of the frontal lobes in first-episode schizophrenia: interaction with clinical course and neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Accounting for dropout bias using mixed-effects models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Type I Error Rates from Mixed Effects Model Repeated Measures versus Fixed Effects Anova with Missing Values Imputed via Last Observation Carried Forward

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Schizophrenia. A follow-up study of the results of five forms of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Psychosis treatment prior to psychosis onset: ethical issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Early detection and intervention with schizophrenia: rationale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

EPPIC: an evolving system of early detection and optimal management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Symptom assessment in schizophrenic prodromal states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

A New Depression Scale Designed to be Sensitive to Change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Risk factors of psychosis: identifying vulnerable populations premorbidly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Treatment histories of patients with a syndrome putatively prodromal to schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Outcome study of first-episode psychosis. I: Relapse rates after 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Preventing severe mental illnesses--new prospects and ethical challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Schizophrenia researchers striving for early detection and intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Course of treatment response in first-episode and chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Effects of development on olanzapine-associated adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The "prodromal" patient: both symptomatic and at-risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Consistency of atypical antipsychotic superiority to placebo in recent clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Neuroleptics and the Natural Course of Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

A rating scale for mania: reliability, validity and sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The initial prodrome in psychosis: descriptive and qualitative aspects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

10.1016/S0006-3223(03)00321-4

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference